Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

ABSTRACT:

Backgrounds

Tamoxifen is typically used to treat patients with estrogen receptor alpha (ERα)-positive breast cancer. However, 30% of these patients gain acquired resistance to tamoxifen during or after tamoxifen treatment. As a Ras modulator, Nogo-B receptor (NgBR) is required for tumorigenesis through the signaling crosstalk with epidermal growth factor (EGF) receptor (EGFR)-mediated pathways. NgBR is highly expressed in many types of cancer cells and regulates the sensitivity of hepatocellular carcinoma to chemotherapy. In this study, we found the expression of NgBR is increased in tamoxifen-resistant ERα-positive breast cancer cells.

Methods

Tamoxifen-resistant ERα-positive MCF-7 and T47D breast cancer cell lines were established by culturing with gradually increased conc

SUBMITTER: Gao P 

PROVIDER: S-EPMC6134690 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature